FDA clears first human epigenetic reprogramming trial in the U.S.
On 2026-06-13, the U.S. Food and Drug Administration's clearance of Life Biosciences' Investigational New Drug application for ER-100 was reported as the first human trial of partial epigenetic reprogramming in the United States. The company said Phase 1 enrollment has begun for patients with open-angle glaucoma and NAION. The event is a discrete regulatory/treatment milestone rather than an outbreak or policy action.
Before you submit
Two confirmations. They live here only — answer once, then we never ask again.
Once accepted, this card never appears again.